<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576575</url>
  </required_header>
  <id_info>
    <org_study_id>201104146</org_study_id>
    <nct_id>NCT01576575</nct_id>
  </id_info>
  <brief_title>Buprenorphine Disposition and Clinical Effects</brief_title>
  <acronym>BUP</acronym>
  <official_title>Influence of CYP3A Modulation on Buprenorphine Disposition and Clinical Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how people absorb and break down (metabolize) and
      eliminate buprenorphine and if CYP3A is involved.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of BPN and metabolites</measure>
    <time_frame>At various times upto 96 hours</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV buprenorphine or sublingual burenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifampin and IV buprenorphine or sublingual burenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifampin and IV buprenorphine or sublingual burenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grapefruit juice and sublingual buprenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoconazole and IV buprenorphine or sublingual burenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoconazole and IV buprenorphine or sublingual burenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV buprenorphine or sublingual burenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>.2 mg IV or 2-4 mg sublingual</description>
    <arm_group_label>Session 2</arm_group_label>
    <arm_group_label>Session 3</arm_group_label>
    <arm_group_label>Session 4</arm_group_label>
    <arm_group_label>Session 5</arm_group_label>
    <arm_group_label>Session 6</arm_group_label>
    <arm_group_label>Session 7</arm_group_label>
    <arm_group_label>Session 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>600 mg orally for 7 days</description>
    <arm_group_label>Session 3</arm_group_label>
    <arm_group_label>Session 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>grapefruit juice</intervention_name>
    <description>8 oz at bedtime and 3oz in the morning.</description>
    <arm_group_label>Session 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>400 mg orally for 3-4 days</description>
    <arm_group_label>Session 6</arm_group_label>
    <arm_group_label>Session 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each subject must meet all of the following criteria:

          1. Male or non-pregnant female volunteer, 18-50 yr old

          2. Good general health with no known major medical conditions

          3. BMI between 20-33

          4. Provide informed consent

        Exclusion Criteria:

        Subjects will not be enrolled if any of the following criteria exist:

          1. Known history of liver or kidney disease

          2. Use of prescription or non-prescription medications, herbals or foods known to be
             metabolized by or affect CYP3A activity (this includes the use of oral
             contraceptives).

          3. Females who are pregnant or nursing

          4. Known history of drug or alcohol addiction (prior or present addiction or addiction
             treatment)

          5. Direct physical access to and routine handling of addicting drugs in the regular
             course of duty (this is a routine exclusion from studies of drugs with addiction
             potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Kharasch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristi Kraus</last_name>
    <phone>314-747-0421</phone>
    <email>krausk@anest.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalin Guebert</last_name>
      <phone>314-747-1663</phone>
      <email>kguebert@anest.wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>to determine how people absorb and break down (metabolize) and eliminate buprenorphine and if CYP3A is involved.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

